Pfizer: marketing authorisation recommended for Comirnaty
(CercleFinance.com) - Pfizer and BioNTech announce that the CHMP of the European Medicines Agency has recommended the conversion of the conditional marketing authorisation (MA) for Comirnaty to a standard MA for all authorised indications and formulations.
In addition, the advisory committee separately recommends approval of the booster dose of the vaccine developed by both groups against Covid-19, in children aged five to 11 years in the European Union.
The European Commission will review the CHMP's recommendations and is expected to make a final decision soon. If the standard MA is granted, the decision will be immediately applicable to the 27 EU Member States.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
In addition, the advisory committee separately recommends approval of the booster dose of the vaccine developed by both groups against Covid-19, in children aged five to 11 years in the European Union.
The European Commission will review the CHMP's recommendations and is expected to make a final decision soon. If the standard MA is granted, the decision will be immediately applicable to the 27 EU Member States.
Copyright (c) 2022 CercleFinance.com. All rights reserved.